Posters

Clinical outcomes of the novel monofocal hydrophilic acrylic intraocular lens Aspira-aXA

Poster Details

First Author: D.Pilger GERMANY

Co Author(s):    C. Münter   E. Bertelmann                 

Abstract Details

Purpose:

To evaluate the visual performance and rotational stability of the Aspira-aXA (HumanOptics AG) with an overall diameter of 11.0 mm, a large optic diameter (7.0 mm) and optimized plate haptics (cut-out haptics) after implantation in cataract patients.

Setting:

Department of Ophthalmology of the Charité - Universitätsmedizin, Berlin, Germany

Methods:

In this prospective study, a total of 36 eyes with senile cataract and eligible for posterior chamber IOL implantation was targeted. The IOLs were manufactured with a toric marking to assess the objective rotational stability and were available in spherical powers of 10.0 to 25.0 D. A standard cataract surgery procedure with an incision size of 2.2 mm and a capsulorhexis of approximately 5.5 mm was performed. Postoperative examinations after 1 day, 1 week, 1 month and 4 months included refraction, visual acuity, IOL rotational stability over 4 months and patient satisfaction.

Results:

Median axial length was 23.88 mm (21.94 to 24.75) and median IOL power was 21.75 D (18.50 to 24.50). Median monocular UDVA and CDVA was 0.00 logMAR (-0.20 to 0.40) and -0.20 (-0.20 to 0.00) logMAR four months postoperatively. There was a median rotation of 2.07° between the end of surgery (EoS) and the 4-month follow-up. Between the postoperative visits (1 day vs 1 week, 1 week vs 1 month and 1 month vs 4 months), a median rotation of less than 1.0° was observed. All patients were very satisfied (84%) or satisfied (16%) with no complaints of photic phenomena.

Conclusions:

The Aspira-aXA with its large optic and cut-out haptics provides good and stable visual performance while allowing standard surgical techniques with small incisions

Financial Disclosure:

research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented